(AOF) – SpineGuard, an innovative company that designs, develops and markets medical devices intended to secure and simplify the placement of bone implants, and Omnia Medical LLC, specializing in the development of innovative solutions for clinically proven surgical techniques, have signed a co-development and exclusive marketing agreement in the field of adult spine surgery in the United States.
This partnership concerns two innovative devices: a system of intelligent pedicle screws and a drilling instrument for ilio sacral fusion, both integrating DSG (Dynamic Surgical Guidance) technology for real-time surgical guidance without the use of X-rays, from SpineGuard. .
Both SpineGuard and Omnia Medical’s missions are aimed at making spinal surgery safer by improving clinical outcomes while reducing the overall cost to healthcare systems.
SpineGuard will present its financial results for the first half of 2022 on September 15, 2022 after market close.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.